<DOC>
	<DOCNO>NCT01092052</DOCNO>
	<brief_summary>The purpose study evaluate safety profile NMS-1116354 , CDC7 kinase inhibitor , adult patient advanced/metastatic solid tumor .</brief_summary>
	<brief_title>Study NMS-1116354 Advanced/Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Advanced/metastatic solid tumor , alternative effective standard therapy available 2 . Maximum 4 regimen prior cancer therapy allow 3 . Prior radiotherapy allow 25 % BM reserve irradiate 4 . Resolution acute toxic effect ( exclude alopecia ) prior anticancer therapy 5 . ECOG performance status ( PS ) 0 1 6 . Adult ( age &gt; /= 18 &lt; /= 80 year ) patient 7 . Adequate renal , liver BM reserve 8 . Capability swallow capsule intact 1 . Current enrollment another therapeutic clinical trial 2 . Known brain metastasis 3 . Currently active second malignancy 4 . Major surgery within 4 week prior treatment 5 . Any following past 6 month : myocardial infarction , unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis 6 . Pregnancy breastfeed woman 7 . Known active infection 8 . Gastrointestinal disease malabsorption syndrome would impact drug absorption 9 . Adrenal insufficiency 10 . Other severe acute chronic medical psychiatric condition could compromise protocol objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Phase I study</keyword>
	<keyword>Advanced/Metastatic Solid Tumors</keyword>
	<keyword>Cdc7 kinase inhibitor</keyword>
</DOC>